Dovitinib in Neuroendocrine Tumors

Unresectable Paraganglioma Clinical Trial

Official title:
A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma

Status Completed

Clinical Trial Summary

This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.

Clinical Trial Description

This investigator-initiated study is being conducted to evaluate whether the investigational drug, Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors (advanced malignant pheochromocytoma or paraganglioma). The primary endpoint will be response rate (Complete + Partial Response) determined by RECIST v 1.1. 25 subjects will be enrolled on this study at the University of Pennsylvania. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01635907
Study type	Interventional
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Completed
Phase	Phase 2
Start date	June 2012
Completion date	April 11, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04394858` - Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer	Phase 2
Withdrawn	`NCT04106843` - Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers	Phase 2
Active, not recruiting	`NCT02302833` - Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery	Phase 2
Active, not recruiting	`NCT02721732` - Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic	Phase 2